Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 5/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.50 |
| ▸ | PHGDH | O43175 | 1/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7099041 | 0.99 | MAPT (0.54) | MAPTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL7104019 | 0.92 | HDAC3 (0.59) | MAPTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL6841073 | 0.89 | HDAC3 (0.48) | MAPTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL14336770 | 0.88 | MAPT (0.57) | MAPTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL14336796 | 0.85 | MAPT (0.52) | MAPTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL14347199 | 0.84 | MAPT (0.50) | MAPTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL14336576 | 0.79 | NPC1 (0.56) | MAPTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL7516731 | 0.79 | MAPT (0.47) | MAPTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL7147082 | 0.75 | SMN1; SMN2 (0.64) | MAPTNPC1ALDH1A1MEN1KMT2A | |
| SCHEMBL7517209 | 0.74 | MAPT (0.54) | MAPTNPC1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339668-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2003-09-03 | — | — | EP | claimed |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | claimed |
| WO-2002044126-A2 | BISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIRUS | GUILFORD PHARMACEUTICALS INC. (US) | 2002-06-06 | — | — | WO | claimed |
| US-7312181-B2 | Acylated thiosemicarbazides as herbicides | CROPSOLUTION, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312181-B2 | Acylated thiosemicarbazides as herbicides | CROPSOLUTION, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | GUILFORD PHARMACEUTICALS, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020127605-A1 | Bisubstituted carbocyclic cyclophilin binding compounds and their use | PPIG, PIN1, PPIH | MAPT 1168/4885NPC1 796/4885ALDH1A1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.